Predictors of long-term outcome after percutaneous mitral commissurotomy (PMC)
| Study | No. of patients | Follow-up (years) | End points | Predictive factors |
|---|---|---|---|---|
| Zimmet et al41 | 243 | 3.2* | MV surgery | MR (post), echo score |
| Song et al45 | 329 | 9.1† | Death, MV surgery or re-PMC | MVA (post), age, commissural MR or splitting |
| Jneid et al46 | 876 | 4.1 | Death, MV surgery or re-PMC | MR‡ (pre) ≥1+, MR (post) ≥2 + |
| Fawzy61 | 547 | 9 | Death, MVR, re-PMC and NYHA ≥3 | Echocardiographic score >8, MVA (post) ≤1.8 cm2 and AF |
| Kim et al52 | 303 | 10 | Death, systemic embolism, admission for heart failure, re-PMC and MV surgery | Age, tricuspid regurgitation (pre), MVA (post), LA volume change (%) and LA volume index (pre) |
| Chmielak et al26 | 132 | 6.3 | Death, MVR, re-PMC and NYHA III/IV | Suboptimal immediate result, age and PAP (post) |
| Martínez et al62 | 225 | 13.5 | Death, surgery, re-PMC and functional impairment (NYHA≥3) | MVA <1.9 cm2 (post) |
| Tomai et al34 | 527 | 11.7 | Primary: death, MV surgery or re-PMCSecondary: functional impairment | Male gender, echo score >8, AF and MVA (post) ≤1.75 cm2 |
| Nunes et al14 | 325 | 2.4 | Death, MVR and re-PMC | Age, MR severity (post), mean gradient (post) and PAP (post) |
| Bouleti et al13 | 1024 | 10.2 | Death, surgery, re-PMC and functional impairment (NYHA≥3) | Calcification grade ≥3, age, AF, NYHA ≥3 and MV gradient (post) |
*Median duration of follow-up, range 0–153 months.
†Median duration of the clinical follow-up. The median duration of echocardiographic follow-up was 74 months.
‡Sellers’ classification. Death, surgery, re-PMC and functional impairment (NYHA≥3).
AF, atrial fibrillation; LA, left atrium; MR, mitral regurgitation; MV, mitral valve; MVA, mitral valve area; MVR, mitral valve replacement; NYHA, New York Heart Association functional class; PAP, pulmonary artery pressure.